A T-cell engaging bispecific antibody with a tumor-selective bivalent folate receptor alpha binding arm for the treatment of ovarian cancer

Autor: Brian C. Avanzino, Kirthana Prabhakar, Pranjali Dalvi, Sharon Hartstein, Hannes Kehm, Aarti Balasubramani, Andrew A. Boudreau, Ben Buelow, Karen Chang, Laura M. Davison, Suhasini Iyer, Vidyut Kalwit, Kristin Lewis Wilson, Harbani K. Malik-Chaudhry, Will Pierson, Geovanni Pineda, Udaya S. Rangaswamy, Sowmya Saiganesh, Ute Schellenberger, Harshad S. Ugamraj, Rodolfovan D. Yabut, Roland Buelow, Jocelyn Chapman, Nathan D. Trinklein, Katherine E. Harris

Publikováno v: OncoImmunology, Vol 11, Iss 1 (2022)

The use of T-cell engagers (TCEs) to treat solid tumors is challenging, and several have been limited by narrow therapeutic windows due to substantial on-target, off-tumor toxicities due to the expression of low levels of target antigens on healthy t

Externí odkaz: https://doaj.org/article/9e96f15bb0a54d7bb137adf3be604c3c

Liver-specific mitochondrial amidoxime–reducing component 1 (Mtarc1) knockdown protects the liver from diet-induced MASH in multiple mouse models.

Autor: Yuanjun Guo, Zhengyu Gao, LaGory, Edward L., Kristin, Lewis Wilson, Gupte, Jamila, Yan Gong, Rardin, Matthew J., Tongyu Liu, Nguyen, Thong T., Long, Jason, Yi-Hsiang Hsu, Murray, Justin K., Lade, Julie, Jackson, Simon, Jun Zhang

Publikováno v: Hepatology Communications; 2024, Vol. 8 Issue 5, p1-15, 15p

Contributors

Autor: Rick Adler, Famke Aeffner, Laura E. Armstrong, Dmitri Artemov, Adam D. Aulbach, Bindu M. Bennet, Eric A. Blomme, Brad Bolon, Christopher J. Bowman, Molly Boyle, Alys Bradley, Dino Bradley, Danielle Brown, Pierre R. Bushel, Ellen Cannady, Mark F. Cesta, Curtis Chan, Jennifer A. Chilton, Peter J.M. Clements, Torrie A. Crabbs, Myrtle A. Davis, Sandy Eldridge, Daniela Ennulat, Jeffrey Everitt, Isabel Figueroa, James D. Fikes, Thomas Forest, Catherine A. Foss, John R. Foster, Kathleen Gabrielson, Shayne C. Gad, Kapil Gadkar, Jinping Gan, David Garcia-Tapia, Frank J. Geoly, Wendy G. Halpern, Jerry F. Hardisty, Wanda M. Haschek, Kathleen Marie Heinz-Taheny, Kristi Helke, Lauren E. Himmel, Mark J. Hoenerhoff, Jennifer L. Ingram–Ross, Armando R. Irizarry Rovira, Evan B. Janovitz, Kishore Katyayan, Charlotte M. Keenan, Angela King-Herbert, Steven T. Laing, Lois D. Lehman-McKeeman, Na Li, Calvert Louden, Claire Lyons, Kevin McDorman, Elizabeth McInnes, Lyn Miller Wancket, Sheroy Minocherhomji, Sébastien Monette, James Morrison, Vasanthi Mowat, Sydney Mukaratirwa, Keith Nelson, Arun R. Pandiri, Tracey Papenfuss, Nita Patel, Daniel J. Patrick, Shari A. Price, Deepa B. Rao, James T. Raymond, Jennifer Rojko, Colin G. Rousseaux, Sara F. Santagostino, Aaron Sargeant, Christina Satterwhite, A. Eric Schultze, Vanessa Schumacher, Cheryl Scudamore, Keith R. Shockley, Bhanu P. Singh, David M. Stresser, Polina Sysa-Shah, Debra A. Tokarz, Terry Van Vleet, Matthew A. Wallig, Jin Wang, Cynthia J. Willson, Kristin Lewis Wilson, Christopher T. Winkelmann, Jeffrey C. Wolf, Charles Wood, Daniela Bumbaca Yadav, Mark Zarella

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::c3831ed61c4599a4d47034bfb7e19d99
https://doi.org/10.1016/b978-0-12-821044-4.01002-5

Chapter 23 - Genetically Engineered Animal Models in Toxicologic Research

Autor: Himmel, Lauren E., Wilson, Kristin Lewis, Santagostino, Sara F., Bolon, Brad

Publikováno v: In Haschek and Rousseaux's Handbook of Toxicologic Pathology Edition: Fourth Edition. 2022:859-924

Abstract 5202: AMG 794, a Claudin 6-targeted half-life extended (HLE) bispecific T cell engager (BITE®) molecule for non-small cell lung cancer and epithelial ovarian cancer

Autor: Elizabeth Pham, Anja Henn, Beate Sable, Joachim Wahl, Kip Conner, Katja Matthes, Shivani Gupta, Rodolfo Yabut, Famke Aeffner, Kristin Lewis Wilson, Jonas Anlahr, Christoph Dahlhoff, Vijay Kale, Matthias Friedrich, Tobias Raum, Peter Kufer, Angela Coxon, Sabine Stienen, Julie M. Bailis

Publikováno v: Cancer Research. 82:5202-5202

AMG 794 is a half-life extended BiTE® immune therapy targeting the oncofetal antigen Claudin 6 (CLDN6). AMG 794 redirects T cells to kill CLDN6-expressing tumor cells and is being developed for the treatment of non-small cell lung cancer (NSCLC) and

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::5839cf4bdc1b3b6f509a905ebca97cbb
https://doi.org/10.1158/1538-7445.am2022-5202